Skip to content
InsideEdge
Investors / filer profile

Track record

What happened ~6 months after each disclosed buy

Not enough completed buys to draw the outcome line yet.

0 of 1
buys higher ~6mo later
-0.3%
median outcome
+9.0%
S&P 500 median, same spans

1 buy still inside the ~6-month window — not scored yet.

Disclosed positions

Estimated from their latest filings — positions may have changed since

$98.51M
combined est. value

Activity

Open-market buy & sell volume

BuySell
0$42.3M$84.5M2025 · bought $30.0M · sold $84.5M20252026 · bought $25.0M · sold $02026
Total +$55.00M bought · $84.54M sold
Most bought

All filings on record

Every Form 4 transaction we track for this filer

NUVLGrant
2026-06-16 · Nuvalent, Inc.
3,444
PBLSConvert
2026-06-11 · Parabilis Medicines, Inc.
407,132
PBLSConvert
2026-06-11 · Parabilis Medicines, Inc.
407,132
PBLSConvert
2026-06-11 · Parabilis Medicines, Inc.
260,992
PBLSConvert
2026-06-11 · Parabilis Medicines, Inc.
260,992
PBLSConvert
2026-06-11 · Parabilis Medicines, Inc.
149,238
PBLSConvert
2026-06-11 · Parabilis Medicines, Inc.
149,238
PBLSConvert
2026-06-11 · Parabilis Medicines, Inc.
122,990
PBLSConvert
2026-06-11 · Parabilis Medicines, Inc.
122,990
LRMRBuy
2026-02-27 · Larimar Therapeutics, Inc.
$10.00M
in progress
LRMRBuy
2026-02-27 · Larimar Therapeutics, Inc.
$4.16M
in progress
LRMRBuy
2026-02-27 · Larimar Therapeutics, Inc.
$5.42M
in progress
LRMRBuy
2026-02-27 · Larimar Therapeutics, Inc.
$5.42M
in progress
NUVLSell
2025-11-24 · Nuvalent, Inc.
$35.44M
NUVLSell
2025-11-24 · Nuvalent, Inc.
$35.44M
LRMRBuy
2025-07-31 · Larimar Therapeutics, Inc.
$8.32M
-0.3%
LRMRBuy
2025-07-31 · Larimar Therapeutics, Inc.
$10.84M
-0.3%
LRMRBuy
2025-07-31 · Larimar Therapeutics, Inc.
$10.84M
-0.3%
SPRYSell
2025-06-27 · ARS Pharmaceuticals, Inc.
$6.83M
SPRYSell
2025-06-27 · ARS Pharmaceuticals, Inc.
$6.83M
NUVLGrant
2025-06-18 · Nuvalent, Inc.
2,647
NUVLGrant
2025-06-18 · Nuvalent, Inc.
2,647

Outcomes measure each disclosed buy against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.